Source brief: Organic acid analysis in the clinical laboratory
Clinical-laboratory context for organic acid analysis and why test interpretation depends on indication and method.
Read the source briefPlain-English answers on peptides, rapamycin, NAD, gene therapy, biological age tests and biohacking - with evidence and sources when you want to go deeper.
Simple answers before labels and study detail.
Original sources stay attached to every serious claim.
No dosing, sourcing, stacking or self-administration instructions.
Updated daily
New source briefs, with the original link and the limits kept intact.
Clinical-laboratory context for organic acid analysis and why test interpretation depends on indication and method.
Read the source briefReview context for photobiomodulation and low-level light therapy claims.
Read the source briefSystematic review/meta-analysis of NMN and NR effects on skeletal muscle outcomes.
Read the source briefStart with a simple answer. Open the evidence only if you want more detail.
Simple answer
Not for broad injury recovery in humans. The evidence is still mostly animal, lab or indirect.
Read the simple answerSimple answer
It is a real drug approved for other uses, but human anti-aging benefit is not proven.
Read the simple answerSimple answer
Some may affect NAD biology, but that is not the same as proving they slow aging.
Read the simple answerSimple answer
They can be interesting, but one number should not be treated as proof a protocol works.
Read the simple answerSimple answer
Not in normal consumer use. Most age-reversal gene therapy claims are experimental or misleading.
Read the simple answerSimple answer
The strongest basics are still sleep, exercise, cardiometabolic risk, nutrition and not overreading shiny claims.
Read the simple answerUse the same three-step pattern whenever a claim sounds exciting, scary or too certain.
Name the promise before judging it.
The useful context without making you read a paper first.
The safety, legal and hype boundaries.
You do not need to know the scientific taxonomy. Start with the thing people are talking about.
BPC-157, TB-500, Semax and other claims where approval status, quality and self-experimentation risk matter.
Start hereRapamycin, metformin, acarbose and other real medicines discussed beyond their approved uses.
Start hereNMN, NR, NAD drips and mitochondrial claims separated from marketing language.
Start hereEpigenetic clocks, biomarkers and what a test can or cannot tell one person.
Start hereCRISPR, partial reprogramming and frontier claims with extra care around hype and risk.
Start hereExercise, sleep, protein, cardiometabolic markers and the less glamorous work with better human evidence.
Start hereBeginner-friendly pages for the questions people search before they reach forums or clinic menus.
Profile
BPC-157 is widely discussed because animal and mechanism studies make tissue-repair claims sound plausible, but strong human proof for gym injuries o...
Profile
TB-500 is not proven to speed injury recovery in people.
Guide
A peptide is a short chain of amino acids.
Safety guide
A research peptide is marketed for laboratory or research use, not as an approved human medicine.
Question
Rapamycin, also known as sirolimus, is a real medicine approved for specific uses and a serious geroscience candidate.
Mechanism
NAD is a molecule involved in energy metabolism and repair pathways.
Guide
Biological age is an estimate of aging-related state, not a literal countdown.
Guide
Gene therapy is real medicine for specific diseases, but consumer anti-aging gene therapy is a different and much more speculative claim.
Safe answers to high-intent questions without dosing, sourcing, vendor lists or self-administration instructions.
Based on the kinds of questions people ask in longevity communities, translated into safe, source-aware explainers.
Six recent checks, with deeper evidence inside each page.
peptides
No strong human evidence shows that BPC-157 heals tendon or ligament injuries. Most support is animal, cell or mechanism-based, and internet recovery claims should not be treated as proven clinical benefit.
peptides
TB-500 injury-recovery claims are not supported by strong human clinical evidence. The claim often relies on extrapolation from thymosin beta-4 biology and should be treated as unproven.
Longevity drugs
Rapamycin has unusually strong aging-biology interest, but it is not proven to slow human aging or extend lifespan in healthy adults.
NAD & supplements
NMN may affect NAD-related biomarkers in some studies, but that does not prove it slows human aging. The stronger claim needs clinical outcomes, not only a molecule-level signal.
NAD & supplements
There is no simple evidence-based winner between NR and NMN for longevity. Comparisons depend on dose form, endpoints, product quality and whether the outcome is a biomarker or a health result.
NAD & supplements
NAD IV anti-aging claims are not supported by strong evidence. Infusion marketing often uses cellular language that does not prove meaningful aging outcomes.
More context for readers who want the safe answer and the source trail.
Safety guide
People may encounter BPC-157 through clinic or telehealth offers, compounding claims, international clinics, clinical-trial discussions, social media...
Safety guide
There is no universal safe way to take BPC-157 that this page can give.
Safety guide
There is no single kind of doctor that safely covers every peptide claim.
Regulatory guide
No.
Question
GLP-1-based weight loss can include loss of lean mass, but 'lean mass' is not exactly the same as useful muscle.
Question
Red light therapy, often called photobiomodulation, uses light exposure as a biological signal.
Guide
Some longevity-drug candidates are real, approved medicines.
Guide
NAD biology matters, and some precursors can affect NAD-related measures.
Trackers, source directories and machine-readable indexes are still available - just not the first thing a beginner has to decode.
We ask a simple question first: how close is this claim to proof in real people?
Human evidence and accepted medical use for the specific purpose.
Some human data or strong early evidence, with important questions still open.
Interesting science, but not proof it works in people.
People talk about it, but reliable evidence is weak.
The main story is approval status, legality, quality or risk.
One plain-English email on the claims, studies and regulatory updates worth knowing - without protocols, hype or miracle claims.
No protocols. No miracle claims. No spam.